Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]TGRX-678 Mass Balance Study in Healthy Male Adults
NCT06986772Phase 1Completed
- Sponsor
- Shenzhen TargetRx
- Start
- Jul 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TGRX-678 in chronic myeloid leukemia (CML), sponsored by Shenzhen TargetRx. Primary endpoints: Urine radioactivity, Fecal radioactivity and 6 more. Started Jul 2025; status: completed.
02
Drugs
TGRX-678
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT06986772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986772.